Tilray Brands, Inc. TLRY

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
45/100
Developing

Ranked against 90 peers in Drug Manufacturers - Specialty & Generic

About Tilray Brands, Inc.

Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, … Full TLRY analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.81), suggesting sticky customer base.
  • Operating Leverage in Effect Operating leverage is evident (score 0.69), with margins expanding over time.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 21.2th percentile with high volatility suggests weak pricing power or commoditized products.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.38), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
22
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where TLRY ranks in Drug Manufacturers - Specialty & Generic

Tilray Brands, Inc. ranks #40 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 44%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

# Company Moat score Rating
36 Rockwell Medical, Inc. RMTI 47/100 Developing
37 Evotec SE EVO 47/100 Developing
38 Eton Pharmaceuticals, Inc. ETON 46/100 Developing
39 Cronos Group Inc. Common Share CRON 46/100 Developing
40 Tilray Brands, Inc. TLRY 45/100 Developing
41 Organigram Holdings Inc. OGI 45/100 Developing
42 Perrigo Company plc PRGO 43/100 Developing
43 Viatris Inc. VTRS 43/100 Developing
44 Intercure Ltd. INCR 42/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How TLRY scores on the Corporate Default defenses

Pricing Power

Score 22 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 62 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 58 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 37 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 52 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 50 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding TLRY's moat

What is Tilray Brands, Inc.'s moat score?

Tilray Brands, Inc. (TLRY) scores 45 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #40 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 44%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Cost Advantage (62/100) and its weakest is Pricing Power (22/100).

How does Tilray Brands, Inc. compare with other Drug Manufacturers - Specialty & Generic companies?

Tilray Brands, Inc. ranks #40 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Cronos Group Inc. Common Share (CRON) at 46 just above it and Organigram Holdings Inc. (OGI) at 45 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Tilray Brands, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Tilray Brands, Inc.?

The Corporate Default template measures 6 defenses, and TLRY scores: Pricing Power (22), Cost Advantage (62), Customer Stickiness (58), Capital Efficiency (37), Resilience (52), Scale & Market Position (50). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000